Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | KDM5A | P29375 | 5/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.38 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | LSS | P48449 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12342360 | 0.85 | TDP1 (0.35) | CES2KDM5AKDM4C | |
| SCHEMBL24486203 | 0.82 | BLM (0.34) | KDM5AKDM4C | |
| SCHEMBL20234217 | 0.80 | CES2 (0.40) | CES2KDM5AKDM4CMAOBS1PR2 | |
| SCHEMBL19963552 | 0.80 | CES2 (0.40) | CES2PLA2G4BNAAA | |
| SCHEMBL15315161 | 0.77 | CES2 (0.67) | CES2PLA2G4BNAAAMEN1KMT2A | |
| SCHEMBL23064089 | 0.77 | CES2 (0.67) | CES2PLA2G4BNAAAMEN1KMT2A | |
| SCHEMBL15315165 | 0.77 | CES2 (0.67) | CES2PLA2G4BNAAAMEN1KMT2A | |
| SCHEMBL23064078 | 0.77 | CES2 (0.67) | CES2PLA2G4BNAAAMEN1KMT2A | |
| SCHEMBL15315159 | 0.77 | CES2 (0.67) | CES2PLA2G4BNAAAMEN1KMT2A | |
| SCHEMBL22006241 | 0.75 | CES2 (0.39) | CES2KDM5AKDM4CS1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180147202-A1 | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147202-A1 | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE | TBK1, TBKBP1, TNKS | CES2 4513/4885KDM5A 1229/4885KDM4C 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.